Is 0.04 PSA Considered Undetectable?

A PSA of 0.04 ng/mL falls at or below the threshold most laboratories and clinical guidelines use to define “undetectable” after prostate cancer treatment. But the honest answer is more nuanced than a simple yes, because “undetectable” is not a fixed biological boundary. It depends on which assay your lab uses, what cutoff your urologist applies, and whether your prostate was removed surgically or treated with radiation. At 0.04 ng/mL you are in a zone where the measurement itself starts bumping against the limits of the technology, and where tiny differences in lab platforms can shift a reading from “undetectable” to “detectable” without any real change in your body.

Why “Undetectable” Does Not Mean One Universal Number

When clinicians say your PSA is “undetectable,” they mean it falls below the reporting threshold of the assay their lab happens to use. Different platforms set that floor at different levels. A large study tracking men after radical prostatectomy used an undetectable cutoff of 0.05 ng/mL or below, noting that some participating laboratories set it at 0.02 ng/mL while others used 0.05 ng/mL.¹ Another study explicitly defined undetectable PSA as 0.04 ng/mL or below, categorizing anything from 0.05 to 0.14 ng/mL as “measurable.”² So under one lab’s rules, your 0.04 is firmly undetectable; under another’s, it might register as right at the edge.

The reason for the variation is partly technical and partly biological. The analytic lower detection limit of ultrasensitive PSA assays, meaning the lowest concentration the machine can physically distinguish from zero, ranges from about 0.01 to 0.09 ng/mL depending on the platform. But the biologic lower detection limit, which accounts for background PSA present in people who have never had a prostate, runs much higher. One study testing six ultrasensitive assays on sera from women and castrated men found biologic detection limits of 0.03 to 0.69 ng/mL, up to 30-fold above the analytic floor.³ That means some of the PSA your body produces at 0.04 ng/mL may not even be coming from prostate tissue at all.

Where 0.04 Sits After Radical Prostatectomy

If you have had your prostate surgically removed, the context changes the meaning of every decimal point. The goal after radical prostatectomy is for PSA to fall to essentially zero, because the organ that manufactures the vast majority of PSA is gone. In practice, most doctors treat any PSA consistently below about 0.1 ng/mL as reassuring in the early follow-up period. A value of 0.04 ng/mL comfortably fits that picture.

Where things get more interesting is when ultrasensitive assays are used to detect recurrence earlier than standard tests can. Research on post-prostatectomy monitoring found that an ultrasensitive PSA of 0.03 ng/mL or greater on the first postoperative draw was the optimal threshold for predicting who would go on to develop conventional biochemical relapse. That threshold carried a hazard ratio of roughly 8.5, meaning men whose first reading was 0.03 or above had about eight and a half times the risk of eventual relapse compared to men whose first reading was lower.⁴ By that metric, a first postoperative reading of 0.04 ng/mL would sit just above the threshold the researchers identified as most predictive.

That does not mean a single reading of 0.04 after surgery automatically signals trouble. A one-time value can be influenced by assay noise, lab variability, or traces of non-cancerous tissue. What matters far more is the trend. If 0.04 is your first postoperative reading and it stays flat or drifts downward over months, most urologists would regard that as stable. If it creeps to 0.06, then 0.09, then higher, that rising pattern is what triggers concern about recurrence, regardless of whether any single number crosses a bright line.

After Radiation Therapy the Rules Are Different

If your treatment was radiation rather than surgery, 0.04 ng/mL means something quite different, because you still have a prostate. Irradiated prostate tissue continues to produce some PSA, so the post-treatment goal is not zero but rather a low stable level called a nadir. PSA typically drifts down gradually over months or even years after radiation, and the nadir varies widely from person to person.

Biochemical recurrence after radiation is defined by what is known as the Phoenix criteria: a rise of 2 ng/mL or more above whatever your lowest post-treatment PSA turns out to be.⁵ If your nadir is 0.04, recurrence would not be flagged until your PSA climbed to at least 2.04 ng/mL. In this context a reading of 0.04 is exceptionally good. It reflects a very deep nadir that gives you a wide margin before anyone would invoke the recurrence definition.

Newer, more precise forms of radiation like stereotactic body radiation therapy tend to produce even lower nadirs than older techniques, which has sparked discussion about whether the Phoenix threshold of nadir plus 2 is too generous for these patients.⁶ But even if stricter cutoffs eventually replace Phoenix for certain treatments, a nadir of 0.04 after radiation would still be regarded as an excellent response.

Why Two Labs Can Give You Different Numbers From the Same Blood

One underappreciated source of anxiety around ultra-low PSA values is that different lab platforms can produce meaningfully different readings from the same sample. A study comparing five widely used PSA assays found that one platform underestimated readings by an average of about 21% compared to the reference assay, while another overestimated by roughly 10%.⁷ At higher PSA levels this kind of percentage swing barely matters clinically. At 0.04 ng/mL, a 20% swing is the difference between 0.03 and 0.05, which could push you from “undetectable” to “detectable” on paper without any biological change.

This is why most guidelines emphasize that you should have your PSA drawn at the same lab using the same assay platform over time. Comparing a 0.04 from one manufacturer’s system with a 0.06 from another tells you almost nothing about whether your PSA is actually rising. If you switch doctors or move to a new city and your lab changes, your urologist may want to establish a new baseline rather than comparing directly to old values.

Non-Cancerous Sources of Ultra-Low PSA

Even after complete prostate removal, a small amount of PSA can appear in the blood without any cancer being present. PSA was originally named “prostate-specific antigen,” but the protein turns out not to be specific to the prostate at all. It is produced in small quantities by tissues including breast, kidney, and salivary glands. Seminal plasma contains about a million micrograms per liter, but female breast nipple aspirate fluid can contain up to about 5,000 micrograms per liter, and even lactating women produce measurable PSA in milk.⁸ These non-prostatic sources generally contribute only trace amounts to serum, but at the ultra-low levels we are discussing, even traces can register.

Another possible source after surgery is a small amount of benign prostate tissue left behind at the surgical margin. Some men have microscopic residual glandular tissue that produces a faint PSA signal. A study specifically investigating this found that the presence of benign glandular tissue at the margin was not independently associated with detectable PSA or with biochemical recurrence.⁹ In other words, even if leftover benign tissue is contributing a sliver of PSA at the 0.04 level, it does not appear to predict cancer recurrence on its own.

When Low-Level PSA Readings Are Outright Wrong

Rarely, a PSA reading at ultra-low levels can be a technical artifact rather than a biological signal. Two known culprits deserve mention because they can cause genuine confusion for patients and doctors alike.

The first is heterophile antibody interference. Some people carry naturally occurring antibodies, particularly human anti-mouse antibodies, that can cross-react with the mouse-derived antibodies used inside PSA immunoassays. In one documented case, these antibodies produced a falsely elevated PSA reading of over 2 ng/mL after radical prostatectomy, triggering a recurrence workup for cancer that was not there.¹⁰ The false elevation in that case was dramatic, but subtler interference could nudge a reading from below detection to just above it.

The second is biotin, found in many over-the-counter multivitamins and hair-skin-nail supplements. High-dose biotin can interfere with streptavidin-based immunoassays, a common design in PSA testing platforms. While the levels of biotin in a typical multivitamin (around 300 micrograms) are well below the threshold thought to cause problems (roughly 10 milligrams per day), patients taking high-dose biotin supplements for other reasons could see distorted results.¹¹ If you are taking a biotin supplement at high doses, mention it to your doctor before your PSA draw. In some cases labs will ask you to stop biotin for a couple of days beforehand.

What Happens If PSA Starts Rising From 0.04

The clinical question most men really want answered is: if my PSA is 0.04 now, how worried should I be if it starts to climb? After prostatectomy, the widely used definition of biochemical recurrence is a confirmed PSA of 0.2 ng/mL or above. That is a long way from 0.04, and many men with ultra-low postoperative readings never reach that point. But the trend matters more than any single reading.

A persistently detectable PSA, defined as 0.1 ng/mL or greater that never falls to undetectable after surgery, is a distinct clinical situation. In a large cohort of over 30,000 men after prostatectomy, about 5% had a persistent PSA at their first postoperative assessment. The median persistent PSA was 0.30 ng/mL for men whose pre-surgery PSA was 20 or below, and 0.65 ng/mL for men with higher pre-surgery values.¹² A value of 0.04 does not meet the persistent PSA definition and is far below these medians, which is reassuring.

For men whose PSA does begin rising from ultra-low levels, the question becomes when to act. Early salvage radiation therapy, given before PSA climbs very high, offers the best chance of long-term control. A study comparing outcomes of early salvage radiation in men with low persisting or slowly increasing PSA found that oncological outcomes, including biochemical progression-free survival and overall survival, were similar whether the trigger was a persistent low reading or a rising pattern, and metastasis rates were very low in both groups.¹³ The takeaway is that acting early, while PSA is still in the very low range, tends to produce favorable outcomes regardless of the exact pattern of the rise.

Can Imaging Find Anything at PSA 0.04?

One of the frustrations of an ultra-low but potentially rising PSA is that traditional imaging, such as CT scans and bone scans, is essentially useless at detecting recurrence at these levels. A recurrence producing a PSA of 0.04 involves such a tiny volume of tissue that it falls well below what conventional imaging can see.

PSMA PET/CT, a newer imaging technology that targets a protein on prostate cancer cells, has dramatically improved detection at low PSA levels. Even so, performance declines substantially at the lowest PSA values. One study using extended-field-of-view PSMA PET/CT found a detection rate of about 67% at PSA levels below 0.2 ng/mL, rising to 75% at 0.2 to 0.5 ng/mL and 95% at 1.0 to 2.0 ng/mL.¹⁴ Total-body PET scanners, which image the entire body in one pass with higher sensitivity, have pushed detection rates for men with PSA below 0.2 ng/mL even higher, to roughly 74%, compared to about 44% with standard shorter-field scanners.¹⁵

At a PSA of 0.04 specifically, you are at the very bottom of the below-0.2 bracket. Detection rates would be lower still. Most clinicians would not order PSMA PET at a stable 0.04 because the yield is too low and the reading is within the undetectable range for most assays. But if your PSA is clearly trending upward from 0.04 and your doctor wants to localize a potential recurrence before starting salvage therapy, PSMA PET with a total-body or extended-field scanner is the most sensitive tool currently available.

Practical Advice for Living With an Ultra-Low PSA

If your PSA report says 0.04 ng/mL, the most useful things you can do are straightforward. First, confirm that your lab is using the same assay platform each time you are tested. A change in platform can create an artificial jump or drop that has nothing to do with your cancer status. Second, pay attention to the trend over multiple draws rather than fixating on any single number. A stable 0.04 over six months or a year is a very different story from a 0.04 that was 0.02 three months ago and becomes 0.06 three months later. Third, if you take high-dose biotin supplements, tell your urologist, as this can occasionally interfere with the test.

Finally, keep the numbers in perspective. At 0.04 ng/mL you are in a range that most clinical definitions consider undetectable, that most outcome studies associate with favorable long-term prognosis, and that falls well below the thresholds used to define biochemical recurrence after either surgery or radiation. The anxiety that ultra-low PSA monitoring generates is real, and the differences between 0.02 and 0.04 and 0.06 can feel enormous when you are the person waiting for the lab result. Understanding that these tiny fluctuations are often just noise from the test itself, rather than signals from cancer, can help keep that anxiety in proportion to the actual risk.